Partners L P/Ilbiotechnolog... Net Worth

The estimated Net Worth of Partners L P/Ilbiotechnolog... is at least $358 Milión dollars as of 15 November 2023. Partners Ilbiotechnolog owns over 1,227,301 units of Cullinan Oncology stock worth over $9,869,905 and over the last 5 years Partners sold CGEM stock worth over $347,810,364.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Partners Ilbiotechnolog CGEM stock SEC Form 4 insiders trading

Partners has made over 63 trades of the Cullinan Oncology stock since 2020, according to the Form 4 filled with the SEC. Most recently Partners bought 1,227,301 units of CGEM stock worth $6,246,962 on 15 November 2023.

The largest trade Partners's ever made was selling 8,500,000 units of Cullinan Oncology stock on 9 August 2022 worth over $52,020,000. On average, Partners trades about 588,617 units every 15 days since 2020. As of 15 November 2023 Partners still owns at least 548,938 units of Cullinan Oncology stock.

You can see the complete history of Partners Ilbiotechnolog stock trades at the bottom of the page.

Insiders trading at Cullinan Oncology

Over the last 4 years, insiders at Cullinan Oncology have traded over $29,405,190 worth of Cullinan Oncology stock and bought 2,950,136 units worth $38,299,215 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Ansbert Gadicke a Morana Jovan Embiricos. On average, Cullinan Oncology executives and independent directors trade stock every 14 days with the average trade being worth of $914,589. The most recent stock trade was executed by Jennifer Michaelson on 5 September 2024, trading 8,000 units of CGEM stock currently worth $144,720.

What does Cullinan Oncology do?

Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the treatment of solid tumors; CLN-978, a T cell engaging antibody for B-cell malignancies; Opal, a bispecific fusion protein to block the PD-1 axis, and to activate the 4-IBB/CD137 pathway on T cells in tumors; and Jade, a cell therapy to target a novel senescence and cancer-related protein. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Complete history of Partners Ilbiotechnolog stock trades at CTI BioPharma Corp, Cytokinetics Inc, CytomX Therapeutics Inc, Five Prime Therapeutics Inc, GlycoMimetics Inc, Infinity Pharmaceuticals, Merus N.V, Novus Therapeutics Inc, XOMA Royalty, IDEAYA Biosciences, Repare Therapeutics, Principia Biopharma, Kymera Therapeutics, Olema Pharmaceuticals a Cullinan Oncology

Cullinan Oncology executives and stock owners

Cullinan Oncology executives and other stock owners filed with the SEC include:

• Dr. Patrick A. Baeuerle Ph.D.,
  Co-Founder & Acting Chief Scientific Officer of Biologics
• Owen P. Hughes Jr.,
  Strategic Advisor
• Dr. Jeffrey Jones M.B.A., M.D., M.P.H.,
  Chief Medical Officer
• Steve Andre,
  Chief HR Officer
• Rose Weldon,
  VP of Communications
• Kerry Whalen,
  Sr. Director of Preclinical & Early Devel.
• Dr. Jennifer Michaelson Ph.D.,
  Chief Devel. Officer of Biologics
• Leigh Zawel Ph.D.,
  Chief Scientific Officer of Small Molecules
• Corinne Savill Ph.D.,
  Acting Chief Bus. Officer
• Raymond T. Keane,
  Chief Legal Officer & Sec.
• Nate Nguyen,
  Director of Accounting & Controller
• Jeffrey Trigilio,
  CFO & Treasurer
• Nadim Ahmed,
  Pres, CEO & Director
• Vision Scs Jovan Embiricos ...,
  
• Anthony Rosenberg,
  
• Morana Jovan Embiricos,
  10% owner
• Jacquelyn L Sumer,
  Chief Legal Officer
• Nadim Ahmed,
  President and CEO
• Raymond T Keane,
  Chief Legal Officer
• Jon Marc Wigginton,
  Chief Medical Officer
• Owen Hughes,
  President and CEO
• Leigh Zawel,
  See Remarks
• Morana Globeways Holdings L...,
  
• Ansbert Gadicke,
  Director
• Oncology Impact Fund L.P.On...,
  
• Oncology Impact Fund L.P.On...,
  
• Partners L P/Ilbiotechnolog...,
  
• Jennifer Michaelson,
  Chief Scientific Officer
• David P. Ryan,
  
• Patrick Baeuerle,
  Chief Scientific Officer
• Bioscience I 2017 Ltd Jovan...,
  
• Stephen W Webster,
  
• Thomas Ebeling,
  
• Anne Marie Martin,
  
• Jeffrey Trigilio,
  Chief Financial Officer
• Jeffrey Alan Jones,
  Chief Medical Officer
• Corrine Savill,
  Chief Business Officer
• Mary Kay Fenton,
  Chief Financial Officer
• David D. Meek,
  
• Mary Thistle,